Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: An observational clinical cohort study

Journal of the American College of Cardiology

Volumn 60, Issue 23, 2012, Pages 2384-2390

  Seicean, Sinziana ^a,b   Seicean, Andreea ^b   Plana, Juan Carlos ^a   Budd, G Thomas ^a   Marwick, Thomas H ^a,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TASMANIA   (Australia)

Author keywords

anthracyclines; breast cancer; heart failure; statins

Indexed keywords

ANTHRACYCLINE; ANTHRACYCLINE ANTIBIOTIC AGENT; AROMATASE INHIBITOR; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE CONTROL; DISEASE DURATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HAZARD RATIO; HEART EJECTION FRACTION; HEART FAILURE; HOSPITALIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PILOT STUDY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TREATMENT RESPONSE;

ANTHRACYCLINES; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MIDDLE AGED; OHIO; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84870485453     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.07.067     Document Type: Article

References (34)

1. M.H. Chen, S.D. Colan, L. Diller Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers Circ Res 108 2011 619 628
2. National Cancer Institute Breast cancer 2010 http://www.cancer.gov/ cancertopics/types/breast Accessed January 14, 2011
3. S.M. Shankar, N. Marina, M.M. Hudson Cardiovascular Disease Task Force of the Children's Oncology Group Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group Pediatrics 121 2008 e387 e396
4. S.M. Swain, F.S. Whaley, M.S. Ewer Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials Cancer 97 2003 2869 2879 (Pubitemid 36605157)
5. J.R. Carver, C.L. Shapiro, A. Ng American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects J Clin Oncol 25 2007 3991 4008 (Pubitemid 47477279)
6. B.V. Jensen Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer Semin Oncol 4 2006 15 21 (Pubitemid 43866216)
7. D. Cardinale, A. Colombo, M.T. Sandri Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition Circulation 114 2006 2474 2481 (Pubitemid 44901520)
8. D. Cardinale, A. Colombo, C.M. Cipolla Preventions and treatment of cardiomyopathy and heart failure in patients receiving cancer chemotherapy Curr Treat Cardiovasc Med 10 2008 486 495
9. A.H. Blaes, P. Gaillard, B.A. Peterson, D. Yee, B. Virning Angiotensin converting inhibitors may be protective against cardiac complications following anthracycline chemotherapy Breast Cancer Res Treat 122 2010 585 590
10. E.T. Yeh, A.T. Tong, D.J. Lenihan Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management Circulation 109 2004 3122 3131
11. B. Kalyanaraman Iron signaling and oxidant damage Cardiovasc Toxicol 7 2007 92 94 (Pubitemid 47339874)
12. K.B. Wallace Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis Cardiovasc Toxicol 7 2007 101 107 (Pubitemid 47339855)
13. P.M. Ridker, N. Rifai, M. Clearfield Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events N Engl J Med 344 2001 1959 1965 (Pubitemid 32568149)
14. S.P. Jones, Y. Teshima, M. Akao, E. Marban Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocytes Circ Res 93 2003 697 699 (Pubitemid 37288663)
15. A. Riad, S. Bien, D. Westermann Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice Cancer Res 69 2009 695 699
16. A. Sassano, L.C. Platanias Statins in tumor suppression Cancer Lett 260 2008 11 19
17. C. Baigent, A. Keech, P.M. Kearney Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
18. G.C. Fonarow, R.S. Wright, F.A. Spencer National Registry of Myocardial Infarction Investigators Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality Am J Cardiol 96 2005 611 616 (Pubitemid 41207298)
19. S.E. Nissen, S.J. Nicholls, I. Sipahi Effect of very high intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial JAMA 295 2006 1556 1565
20. B. Sadowitz, K. Seymour, M.J. Costanza, V. Gahtan Statin therapy - part II: clinical considerations for cardiovascular disease Vasc Endovascular Surg 44 2010 421 433
21. C. Coulton, N. Colabianchi, T. Cook An analysis of differences in health status measures among neighborhoods within metro counties of Ohio, 2001 http://www.odh.ohio.gov/healthstats/survey/ofhsrfq2cover.aspx Accessed January 14, 2011
22. L.S. Parsons Reducing bias in a propensity score matched-pair sample using Greedy matching techniques Proceedings of the Twenty-Sixth Annual SAS Users Group International Conference, Long Beach, Calif., April 22-25, 2001 2001 SAS Institute Cary, NC
23. M.J. Pencina, R.B. D'Agostino Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation Stat Med 23 2004 2109 2123 (Pubitemid 38968032)
24. Z. Acar, A. Kale, M. Turgut Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy J Am Coll Cardiol 9 2011 988 989
25. D. Wadhwa, N. Fallah-Rad, D. Grenier Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study Breast Cancer Res Treat 117 2009 357 364
26. D.B. Sawyer Is there more to learn from oncology? Examining the implications of anthracyclines effects on the young heart Circulation 121 2010 623 625
27. N.E. Bowles, K.R. Bowles, J.A. Towbin The "final common pathway" hypothesis and inherited cardiovascular disease The role of cytoskeletal proteins in dilated cardiomyopathy Herz 25 2000 168 175 (Pubitemid 30422160)
28. C. Huang, X. Zhang, J.M. Ramil Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress induced myocardial injury in adult mice Circulation 121 2010 675 683
29. M. Yoshida, I. Shiojima, H. Ikeda, I. Komuro Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATN-p53 apoptosis pathway and attenuated by pivastatin through the inhibition of Rac1 activity J Mol Cell Cardiol 47 2009 698 705
30. G. Takemura, H. Fujiwara Doxorubicin-induced cardiomyopathy: from the cardiotoxic mechanisms to management Prog Cardiovasc Dis 49 2007 330 352 (Pubitemid 46295436)
31. M. Takemoto, K. Node, J. Nakagami, Y. Liao, M. Grimm, Y. Takemoto Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy J Clinical Invest 108 2001 1429 1437 (Pubitemid 33091980)
32. C.A. Goard, R.G. Mather, B. Vinepal Differential interactions between statins and p-glycoprotein: implications for exploiting statins as anticancer agents Int J Cancer 127 2010 2936 2948
33. H. Nakamae, K. Tsumura, Y. Terada Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone Cancer 104 2005 2492 2498 (Pubitemid 41691573)
34. H.A. Azim, E. Azambuja, M. Colozza, J. Bines, M.J. Piccart Long-term toxic effects of adjuvant chemotherapy in breast cancer Ann Oncol 22 2011 1939 1947